A 'Good' A1c of 6.1% in a 76-Year-Old With Recurrent Hypoglycemia
A 76-year-old woman with a 15-year history of type 2 diabetes returns for routine follow-up. Her A1c is 6.1%. Medications: metformin 1000 mg twice daily, glipizide 10 mg twice daily, lisinopril, atorvastatin. eGFR 44 mL/min/1.73 m2. She lives alone; her daughter visits weekly. Since the last visit she has had two episodes of hypoglycemia - one in which she became confused and sweaty and her daughter found her on the floor, and another in which EMS was called and her glucose was 42 mg/dL. She has mild cognitive impairment (MoCA 22/30) and has had two falls in six months. She reports she sometimes skips lunch because she is not hungry. Her A1c has been between 6.0% and 6.4% for three years. She asks whether she is doing a good job.
1. Is her A1c at goal? Explain your reasoning about targets for this patient.
Read the worked answer
No - her A1c is below a safe goal for her. The number looks excellent in isolation, which is exactly the trap.
- Standard goal for many nonpregnant adults is below 7%. Less stringent goals (below 8%) are appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbidity, or long-standing diabetes in whom the goal is difficult to achieve
- This patient has at least three features that relax the target: a severe hypoglycemic event requiring EMS, mild cognitive impairment, and falls with a medication that causes hypoglycemia
- Her A1c of 6.1% is therefore not evidence of good control but evidence of overtreatment - the risk of harm from another severe event, arrhythmia, or fall-related fracture now exceeds the benefit of a slightly lower glucose
Her target is an A1c below 8%, with emphasis on avoiding hypoglycemia - a value of 7.5% would be a success, not a regression.
Reasoning: the exam tests goal individualization, not arithmetic. A low A1c in an older adult on a sulfonylurea is a red flag, not a trophy.
2. What medication changes do you make, and in what order?
Read the worked answer
Step 1 - stop glipizide. The sulfonylurea is the most likely cause of both events, especially with skipped meals, declining renal function (drug accumulation), and cognitive impairment that prevents her from recognizing and self-treating symptoms. Stopping it is the single highest-yield action and cannot be deferred.
Step 2 - keep metformin, with renal monitoring. It does not cause hypoglycemia. eGFR 44 means continuing at current or modestly reduced dose is reasonable, with monitoring every three to six months and discontinuation if eGFR falls below 30; hold it during acute illness with dehydration.
Step 3 - if additional lowering is needed later, choose an agent with low hypoglycemia risk. A DPP-4 inhibitor is an easy option in this population, and an SGLT2 inhibitor could be considered for cardiovascular or renal benefit, though its diuretic effect and genital infection risk need to be weighed against her falls and living situation. Insulin should not be added.
Step 4 - safety netting. Hypoglycemia education for her and her daughter, a glucose meter with a low-threshold action plan, meal and activity counseling, and review for other sedating or BP-lowering drugs contributing to falls.
Reasoning: deintensification is an active intervention with a sequence, not simply 'reduce the dose and see.'
3. How will you evaluate whether this change worked, and what do you tell her about her goals?
Read the worked answer
Tell her plainly that she has been doing a good job and that the plan is changing because she has earned a less strict target. Frame the removal of a medicine as a safety improvement, not a withdrawal of care.
Evaluation plan:
- Contact her or her daughter in one to two weeks to confirm no further low readings and no rise in symptomatic hyperglycemia
- Repeat A1c in three months, with the expectation that it will rise to roughly 7-7.5% - pre-empt this so a higher number is not experienced as failure
- Ask specifically about hypoglycemia at every visit; she may not report it spontaneously, and cognitive impairment blunts recognition
- Track falls and any emergency visits as outcomes, not just the A1c
- Recheck eGFR and reassess the medication list at each visit
If the A1c climbs above 8% or she develops symptoms of hyperglycemia (polyuria, weight loss), add back a low-hypoglycemia-risk agent rather than resuming a sulfonylurea.
Reasoning: evaluation for this patient is defined by absence of hypoglycemia and preserved function, not by hitting a lower number.